Jim Walsh

Jim Walsh has 25 years general management experience in the Healthcare industry with particular experience in Diagnostics. He is a Director of Trinity Biotech Plc, (NASDAQ: TRIB) an Irish Diagnostics company and is Executive Chairman of Biosensia Ltd. an Irish Point of Care Diagnostics Company.

Previously Dr. Walsh was Executive Chairman of GenCell Biosystems Ltd, a Genomics platform company, acquired by Becton Dickenson in October 2014. Until 2010 Dr. Walsh was CEO of Stokes Bio Ltd. a company specialising in the area of Molecular Diagnostics, acquired by Life Technologies. Prior to that Dr. Walsh was Non Executive Director of PuriCore Plc. (LSE : PURI), Dr. Walsh is also an investor in and a Director of a number of early stage Life-science Companies.